Directorio

Es posible que algunos contenidos no estén disponibles en español.
403 clinical trials found.
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an experimental drug called navtemadlin (the study drug) is a safe and effective option for people with myelofibrosis (MF). We want to know how well it works when it is combined with ruxolitinib for people who did not get the desired results from ruxolitinib on its own.

Compensation: No
Oncology
Hematologic Malignancies and Cellular Therapy

We are doing this study to see if taking a prebiotic (dietary supplement) can reduce the risk of acute graft-versus-host disease (a common complication) in people who receive an allogeneic stem cell transplant. This study is important because prebiotics are a common and safe dietary supplement, and there is a need for a safe and effective way to reduce graft-versus-host disease after transplant.

Compensation: No
Ages: 18-80
Oncology
Duke University Hospital, Other
Sarcoma

We are doing this study to find out if an experimental drug called INBRX-109 (the study drug) is a safe and effective option for people with unresectable or metastatic conventional chondrosarcoma.

Compensation: No
Oncology

We are doing this study to find out if an experimental drug called SRG-514 (the study drug) is a safe and effective option for breast cancer patients. We want to know if it can reduce the inflammation caused by surgery and allow your body to better heal itself and prevent tumor recurrence. We will also be trying to figure out the best dose of the drug to use.

Compensation: Yes
Ages: 18-110
Duke University Hospital
Gastrointestinal Cancer

We are doing this study to find out whether hepatic artery infusion (HAI) pump therapy with floxuridine and dexamethasone is an effective treatment for cholangiocarcinoma that cannot be removed with surgery and has not been treated yet. We want to find out whether the HAI pump treatment plus GemOx chemotherapy works as well as or better than GemOx alone at extending the time before your disease gets worse.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Genitourinary Cancer

We are doing this study to find the most effective, safe dose of an experimental drug called V940 (the study drug) when it is given with pembrolizumab to people who have had surgery to remove their bladder, kidney, or other organs for muscle-invasive urothelial carcinoma. We want to know how well this combination works compared to taking pembrolizumab on its own.

Compensation: No
Oncology
Skin Cancer - Melanoma

We are doing this study to find out if an experimental drug called V940 (the study drug) is a safe and effective option for melanoma patients who have had surgery when it is given in combination with pembrolizumab. We want to know how well the study drug compares to pembrolizumab taken on its own.

Compensation: No
Oncology
Hematologic Malignancies and Cellular Therapy

We are doing this study to find out if an investigational drug called fostamatinib (the study drug) is beneficial for cGvHD when it is used in combination with a standard of care drug, ruxolitinib. We want to know if the study drug can improve relief from cGvHD symptoms.

Compensation: No
Oncology